Select Page

The Company

Ophelos Therapeutics Pty Ltd, is an
Australian corporation (“Ophelos”)
incorporated in 2020, led by a pioneers in
innovation of biomedical product and
services, supported by a seasoned pharma
management team and respected scientific
research team

Ophelos Tx is a subsidiary of Paspa
Pharmaceuticals Pty Ltd (a plant-derived
pharmaceutical R&D company established
in Melbourne Australia in 1996).

.

Core Technology

Elucidating and exploiting nature’s strategies for glycodiversification and enzyme
catalysis to discover new analogues of existing FDA-approved small molecule
drugs.

Ophelos was formed with the vision of rapidly commercializing proprietary technologies (the “Core Technologies”) it has acquired or licensed and/or developed through its science team. The core technology is what its management and science team consider a disruptive “platform technology” within the pharma industry. This disruptive technology is a proprietary method and process to discover new derivatives of existing well-studied drugs never before discovered, with far more desirable pharmacological properties.

Our Management

Vasilis Paspaliaris

Vasilis Paspaliaris

Chief Executive Officer

Vasilis has worked at and consulted for several pharmaceutical and biotech companies globally. Due to his innovation he has been the founder and director of seven biotech companies since 2000. After finishing his doctorate in pharmacology in 1993 at St Vincent’s Institute of Medical Research at the University of Melbourne, he completed his post-doctoral fellowship at Pfizer Central Research in Connecticut. During this time he was awarded two scholarships from the Australian Dairy Research and Development Organisation, and the National Health and Medical research Council of Australia and two young investigators awards in osteoporosis research from the Australian and New Zealand Bone and Mineral Society, and the International Society for Bone and Mineral Research. After doing his clinical training in Greece, he worked in combat trauma medicine in Africa where he stayed and did humanitarian work in Angola. In 2008, Dr. Paspaliaris received an Appreciation Award from the American Association of Clinical Endocrinologists for his ground-breaking work on adipose-derived stem cells and two certificates of appreciation from the American Academy of Anti-Aging Medicine on his stem cell research and an investigators award from the Hellenic Thoracic Society in what was the first published formal human clinical trial on the effect of mesenchyme stem cells on idiopathic lung fibrosis. Dr. Paspaliaris has published over 25 papers, holds over 7 patents and given lectures in a variety of medical fields, mostly in plant-derived drugs and regenerative medicine. He is currently a Faculty Member for the Master degree program in Clinical Pharmacology and Therapeutics at Democritus University Medical School in Greece. He is a member of the World Society of Interdisciplinary Anti-aging Medicine, the Australian Military Medicine Association and Latin American Stem Cell Society, a Fellow of the Philippine Society of Stem Cell Medicine, a Diplomat of the American Board of Regenerative Medicine, a Fellow of the American Academy of Regenerative Medicine and a Fellow of the Royal Society of Medicine (UK). More recently he has completed postgraduate certificates in Genetic CRISPR Engineering from Harvard University, and two postgraduate certificates in Artificial Intelligence, one from MIT and one form Oxford University. He is the founder and director of Paspa Pharmaceuticals Pty Ltd incorporated in 1996, founder and President of Tithon Biotech Inc incorporated in 2014, and recently the founder and director of Ophelos Therapeutics Pty Ltd.

Peter Milonas

Peter Milonas

Chief Operating Officer

Peter was educated in Melbourne, Australia, firstly at La Trobe University, where he completed a Bachelor Degree (Social Sciences) after undertaking studies across a diverse range of disciplines, including Science, Law and Arts, and later at Monash University, where he completed Pharmaceutical Industry specific Post Graduate (APMA CEP) qualifications. His career followed his passion, Health Care, and for the last 20 years he has worked in the Pharmaceutical Industry, developing extensive knowledge and experience in Sales, Marketing and Management across a number of therapeutic areas and medical sectors such as: Biotechnology, Cosmetic Medicine, Ophthalmology, Women’s Health, Surgical & Capital Equipment, Gastroenterology, CNS, Hospital, Aged Care and Pharmacy. From his early beginnings as a Sales Representative, on the front line, to Business Development, and National Sales & Marketing Management, all the way through to, Chief Operating Officer, and Director, Peter has a complete understanding, and perspective, of the intricate world of the Health Care and Pharmaceutical business. His expertise in this area has been acquired over 2 decades of working for some major Health Care/Pharmaceutical organisations in the industry including: WYETH AYERST and LEDERLE LABORATORIES, international pharmaceutical company, specialising in areas such as, Women’s health, Gastroenterology, Vaccine and CNS markets; ALCON LABORATORIES & SURGICAL, an international company specialising in the discovery, development, manufacture and marketing of surgical devices, vision care products and ophthalmic pharmaceuticals; and AUSTRALASIAN MEDICAL & SCIENTIFIC established with the aim of providing the Australian scientific and medical markets with a range of leading edge products from around the world. In the last two years Peter has been instrumental in the development of the business around the incorporated technologies into Adilyfe as he was working as the Business Development Manager of Adistem, General Manager of Paspa Pharmaceuticals, Director and Vice president of Black Arrow Biotech and Chief Operating Officer of Nereen Healthcare.

George Kolios

George Kolios

Chief Medical and Scientific Officer

Dr. George Kolios is a Professor of Pharmacology in the School of Medicine at the Democritus University of Thrace, Alexandroupolis, Greece. He obtained his first degree in Medicine in 1980. In 1992, he obtained his PhD degree in Gastroenterology from the School of Medicine at the University of Athens, Greece and in 1998, his PhD degree in Pharmacology from the Department of Pharmacology at the University of Bath, United Kingdom. In 1990, he finished his Specialization in Gastroenterology and he first worked as Registrar in Gastroenterology at the Royal United Hospital, Bath, United Kingdom and then as Senior Registrar in the Gastroenterology Department at the Hippokration General Hospital, Athens, Greece. From 1998 till 2001, he worked as Consultant Gastroenterologist at the Royal United Hospital, Bath, and Senior Research Fellow in the Department of Pharmacology at the University of Bath, United Kingdom. In 2001, he was appointed Assistant Professor of Gastroenterology in the School of Medicine at the University of Crete and Visiting Professor in Pharmacology at the University of Bath, United Kingdom. From 2008 till 2013, he was Member of the Scientific Board of Approvals of the Greek National Organization for Medicines. From 2008 till today, he is Professor of Pharmacology in the School of Medicine at the Democritus University of Thrace, Alexandroupolis, Greece. He has organized and directed from 2011 till 2018 the Master’s Degree Program “Clinical Pharmacology and Therapeutics” at the School of Medicine of Democritus University of Thrace. From 2015 till today, he is Member of the Pharmacology Department in the Scientific Institute of the Greek General Medical Council, while from 2017 till 2019, he was President of this Board.
Professor George Kolios is an experienced Clinical Gastroenterologist, and a very productive research scientist, with an extensive work in the area of immunopharmacology, mucosal immunology and fibrosis, mainly focused on the intestinal inflammation and Inflammatory Bowel Diseases. His work has demonstrated that the mucosal epithelium could be a rich source of various inflammatory mediators, including cytokines, chemokines and nitric oxide, which are involved in inflammation and fibrosis, and that these pro-inflammatory systems can be modified by cytokines derived by T-cell population. In addition, his work has been focused on the biology and the role of gut subepithelial myofibroblasts in fibrosis and on the interplay between gut mucosal immunity and microbiota and the development of in vitro models for the study of mucosal immunology, such as cell cultures and intestinal organoids. He has more than 120 papers in peer reviewed journals, which have been cited more than 4500 times with an h-index: 36 and more than 250 announcements and invited lectures in scientific congresses in Greece and abroad.

Contact Us

9A Hall St,
Hawthorn East, VIC 3123

+61 3 9573 8888

Leave A Message